We are live on ! Find out more
ZVRA icon

Zevra Therapeutics
ZVRA

33 hedge funds and large institutions have $104M invested in Zevra Therapeutics in 2015 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 8

14% more funds holding

Funds holding: 29 → 33 (+4)

13% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 8

1% more capital invested

Capital invested by funds: $103M → $104M (+$1.48M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
33
Holders Change
+4
Holders Change %
+13.79%
% of All Funds
0.92%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
12
Increased
9
Reduced
8
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
DM
Deerfield Management
New York
+$6.43M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$3.96M
3
CWG
C WorldWide Group
Denmark
+$3.16M
4
DCM
Driehaus Capital Management
Illinois
+$1.59M
5
DA
DSC Advisors
Illinois
+$1.54M

Top Sellers

1
PCM
Pentwater Capital Management
Florida
-$8.94M
2
VAM
Visium Asset Management
New York
-$5.11M
3
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
-$3.36M
4
GTC
Ghost Tree Capital
New York
-$3.21M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$1.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
DM
1
Deerfield Management
New York
$27.5M +$6.43M +21,003 +31%
BC
2
Broadfin Capital
New York
$15.5M -$536K -1,751 -3%
DA
3
DSC Advisors
Illinois
$12.1M +$1.54M +5,016 +15%
Schroder Investment Management Group
4
Schroder Investment Management Group
United Kingdom
$6.64M -$3.36M -10,969 -34%
Alyeska Investment Group
5
Alyeska Investment Group
Illinois
$5.63M +$641K +2,092 +13%
KCM
6
Kingdon Capital Management
New York
$5.24M +$869K +2,837 +20%
Vanguard Group
7
Vanguard Group
Pennsylvania
$5.15M +$3.96M +12,927 +351%
DCM
8
Driehaus Capital Management
Illinois
$4.23M +$1.59M +5,198 +61%
SFM
9
Sphera Funds Management
Israel
$3.96M -$634K -2,069 -14%
Federated Hermes
10
Federated Hermes
Pennsylvania
$3.88M +$383K +1,250 +11%
CWG
11
C WorldWide Group
Denmark
$3.2M +$3.16M +10,313 New
Wellington Management Group
12
Wellington Management Group
Massachusetts
$3.09M -$1.75M -5,702 -36%
ECM
13
Endurant Capital Management
California
$1.22M -$1.59M -5,185 -57%
EI
14
EAM Investors
California
$1.18M +$1.17M +3,813 New
MCM
15
Moore Capital Management
New York
$969K – – –
KCM
16
Kennedy Capital Management
Missouri
$689K +$680K +2,221 New
BIT
17
BlackRock Institutional Trust
California
$656K +$637K +2,079 +5,775%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$644K +$636K +2,077 New
Millennium Management
19
Millennium Management
New York
$629K +$621K +2,029 New
WMSA
20
Weiss Multi-Strategy Advisers
New York
$533K -$47.8K -156 -8%
ARTA
21
A.R.T. Advisors
New York
$404K +$399K +1,304 New
SIM
22
Spark Investment Management
New York
$371K +$367K +1,200 New
Northern Trust
23
Northern Trust
Illinois
$306K +$302K +987 New
BFA
24
BlackRock Fund Advisors
California
$292K -$7.66K -25 -3%
Morgan Stanley
25
Morgan Stanley
New York
$74K +$16.8K +55 +30%
1
2

ZVRA Hedge Fund Activity: Q3 2015 in Review

33 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q3 2015, worth a combined $104M — up 1.4% from $103M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ZVRA positions and 8 closed out — a net gain of 4 holders — while 9 added to existing stakes and 8 trimmed.

The largest buyer was Deerfield Management, adding an estimated $6.43M. The largest seller was Pentwater Capital Management, exiting entirely with an estimated $8.94M sold.

  • 33 institutional investors held Zevra Therapeutics (ZVRA) as of Q3 2015, up from 29 in Q2 2015.
  • Funds reported $104M of Zevra Therapeutics stock for Q3 2015, up 1.4% quarter-over-quarter.
  • 12 funds opened new Zevra Therapeutics positions in Q3 2015 and 8 closed out, a net change of +4 holders.
  • The largest Zevra Therapeutics buyer in Q3 2015 was Deerfield Management, an estimated $6.43M added.
  • The largest Zevra Therapeutics seller in Q3 2015 was Pentwater Capital Management, an estimated $8.94M sold.

Based on aggregated 13F filings for Q3 2015.